Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
Precision BioSciences, Inc. (DTIL)
Last precision biosciences, inc. earnings: 11/12 07:15 am
Check Earnings Report
Company Research
Source: Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent applications relating to the Company’s PBGENE-HBV program.The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, titled “Engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome.” The ’136 application includes composition of matter claims that, when granted, will encompass the ARCUS nuclease utilized in PBGENE-HBV.The second Notice of Allowance relates to U.S. Patent Application No. 19/273,982, titled “Polypeptide linkers for use in engineered meganucleases.” The ’982 application includes composition of matter claims that, when granted, will encompass any polyp
Show less
Read more
Impact Snapshot
Event Time:
DTIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DTIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DTIL alerts
High impacting Precision BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
DTIL
News
- iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA SubmissionBusiness Wire
- Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
- Precision BioSciences (DTIL) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
DTIL
Earnings
- 3/12/26 - Beat
DTIL
Sec Filings
- 3/17/26 - Form 8-K
- 3/12/26 - Form 10-K
- 3/12/26 - Form 8-K
- DTIL's page on the SEC website